Table 2

Contraceptive use and pregnancy rates in all female patients aged 13–50 years initiated on the Estcourt Hospital Multi-Drug-Resistant Tuberculosis (MDR-TB) treatment programme in 2016 (Cycle 1) and in January–October 2017 (Cycle 2).

ParameterCycle 1 (n (%))*Cycle 2 (n (%))*P value
Patients5658
Mean age at initiation (years)29.3 (range 13–50)31.2 (range 15–44)
HIV seropositivity34 (73.9)23 (74.2)
Complete data available4631
Contraception started prior to referral for MDR-TB treatment11 (23.9)

  • 10 DMPA

  • 1 implant

12 (38.7)

  • 11 DMPA

  • 1 bilateral tubal ligation

0.1641†
Contraception started at the time of MDR-TB treatment initiation0 (0%)12 (38.7)

  • 12 DMPA

<0.0001†
Total number of women who were on long-acting injectable contraceptives by the time their MDR-TB treatment was initiated11 (23.9)24 (77.4)<0.0001†
Pregnancy during treatment3 (6.5)0 (0)0.2690‡

  • *Or unit specified.

  • †Pearson’s Chi-squared test.

  • ‡Fisher’s exact test.

  • DMPA, depot-medroxyprogesterone acetate; HIV, human immunodeficiency virus; MDR-TB, multidrug-resistant tuberculosis.